New Research on Eisai's Antiepileptic Drug Zonegran®(Zonisamide) Presented at European Congress on Epileptology (ECE)

New Research on Eisai's Antiepileptic Drug Zonegran®(Zonisamide) Presented at European Congress on Epileptology (ECE) PR Newswire ®New data on the novel anti-epileptic drug (AED) Zonegran (zonisamide) is presented today at the 10th European Congress on Epileptology (ECE) in London. Since July 2012, zonisamide has been licensed in the EU as a monotherapy for newly diagnosed-adults who have partial seizures, with and [1]without secondary generalisations, and also as an adjunctive therapy. Certain patient population may require additional studies to demonstrate efficacy and safety compared to the general adult population. In elderly patients, caution maybe required when making dose recommendations. Data from elderly patients from the pivotal phase III studies were examined to see if differences could be determined in respect to the use of zonisamide. Findings from the studies showed that the safety and efficacy of zonisamide were similar to those reported in the general adult population. In addition, paediatric patients sometimes require specific dosing regimens, and additional safety and tolerability evidence beyond that available for adult populations. Zonisamide, which does not have paediatric licence, is currently under investigation in a paediatric patient population (6-17 years) for adjunctive use in partial-onset seizures in Europe.